ArticleNature2020
The sprint to solve coronavirus protein structures - and disarm them with drugs.
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Investigating Plasma-Activated Water (PAW) onFood science & nutrition · 2025Article
- Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins.Vaccines · 2022Article
- The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2.bioRxiv : the preprint server for biology · 2022Article
- Hands-on training in structural biology, a tool for sustainable development in Africa series 4.Biology open · 2022Article
- Identification of SARS-CoV-2 surface therapeutic targets and drugs using molecular modeling methods for inhibition of the virus entry.Journal of molecular structure · 2022Article
- Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning.Patterns (New York, N.Y.) · 2022Article
- The bacteriophage decides own tracks: When they are with or against the bacteria.Current research in microbial sciences · 2021Review
- Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease.Angewandte Chemie (International ed. in English) · 2021Review
- Antiviral fungal metabolites and some insights into their contribution to the current COVID-19 pandemic.Bioorganic & medicinal chemistry · 2021Review
- Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of three proteins from SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- DeepTracer for fast de novo cryo-EM protein structure modeling and special studies on CoV-related complexes.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline.Frontiers in molecular biosciences · 2021Article
- The sharing of research data facing the COVID-19 pandemic.Scientometrics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32415276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.